Alternative methods of diagnosing drug resistanced what can they do for me?

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 4, 2011, Pages

  Moore, David A J ^a   Shah, N Sarita ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; COLORIMETRY; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; ENZYMATIC ASSAY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FUNDING; GOOD LABORATORY PRACTICE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; LABORATORY DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 80054730159     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir448     Document Type: Article

References (50)

1. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8:52-8. (Pubitemid 38120706)
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Report No.: WHO/HTM/TB/ 2006.361. Geneva, Switzerland: World Health Organization, 2006.
3. Keshavjee S, Farmer PE. Picking up the pacedscale-up of MDR tuberculosis treatment programs. N Engl J Med 2010; 363:1781-4.
4. Nathanson E, Lambregts-van WC, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12:1389-97. (Pubitemid 44455215)
5. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrugresistant tuberculosis: the perfect storm. J Infect Dis 2007; 196(Suppl 1):S86-107. (Pubitemid 47206088)
6. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80. (Pubitemid 44780738)
7. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33:871-81.
8. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Report No.: WHO/HTM/TB/2010.3. Geneva, Switzerland: World Health Organization, 2010.
9. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830-43.
10. WorldHealthOrganization. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. Report No.: WHO/HTM/TB/2009.422. Geneva, Switzerland: World Health Organization, 2009.
11. World Health Organization. The use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva, Switzerland: World Health Organization, 2007. http://www.who. int/tb/dots/laboratory/policy/en/index3.html. Accessed 16 October 2010.
12. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 2008; 5:e156.
13. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:688-98.
14. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165-74.
15. Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009; 56:103-11.
16. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-37.
17. Minion J, Pai M. Bacteriophage assays for rifampicin resistance detection in Mycobacterium tuberculosis: updated meta-analysis. Int J Tuberc Lung Dis 2010; 14:941-51.
18. Kalantri S, Pai M, Pascopella L, Riley L, Reingold A. Bacteriophage- based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta- analysis. BMC Infect Dis 2005; 5:59.
19. Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:175-83. (Pubitemid 47072054)
20. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62:56-64. (Pubitemid 351865874)
21. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-50. (Pubitemid 44547806)
22. Arias M, Mello FC, Pavon A, et al. Clinical evaluation of the microscopic- observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis 2007; 44:674-80.
23. Shiferaw G, Woldeamanuel Y, Gebeyehu M, Girmachew F, Demessie D, Lemma E. Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2007; 45:1093-7. (Pubitemid 46626469)
24. Mello FC, Arias MS, Rosales S, et al. Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin. J Clin Microbiol 2007; 45:3387-9. (Pubitemid 47585667)
25. Ejigu GS,Woldeamanuel Y, Shah NS, Gebyehu M, Selassie A, Lemma E. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008; 12:332-7. (Pubitemid 351361906)
26. Tovar M, Siedner MJ, Gilman RH, et al. Improved diagnosis of pleural tuberculosis using the microscopic-observation drug-susceptibility technique. Clin Infect Dis 2008; 46:909-12. (Pubitemid 351417197)
27. Ha DT, Lan NT, Wolbers M, et al. Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis in children. PLoS One 2009; 4:e8341.
28. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009; 9:67.
29. Morgan M, Kalantri S, Flores L, PaiM. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.
30. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787-92. (Pubitemid 351490566)
31. Nikolayevsky V, Brown T, Balabanova Y, Ruddy M, Fedorin I, Drobniewski F. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol 2004; 42:4498-502. (Pubitemid 39362362)
32. Miotto P, Piana F, Cirillo DM, Migliori GB. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2008; 46:393-4.
33. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43:3699-703. (Pubitemid 41129648)
34. Hillemann D, Rusch-Gerdes S, Richter E. Application of the Genotype MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 2006; 10:1057-9. (Pubitemid 44378986)
35. Evans J, Stead MC, Nicol MP, Segal H. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 2009; 63:11-6.
36. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
37. World Health Organization. Frequently Asked Questions on XPert® MTB/RIF assay. Geneva, Switzerland: World Health Organization, 2011. . http://www.who.int/tb/laboratory/xpert-faqs.pdf.
38. Foundation for Innovative New Diagnostics. FIND negotiated proces for Xpert® MTB/RIF and country list. Geneva, Switzerland: FIND, 2011. http://www.finddiagnostics.org/programs/find-negotiated-prices/ mtbdrplus.html. Accessed 10 May 2011.
39. Dowdy DW, Lourenco MC, Cavalcante SC, et al. Impact and costeffectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 2008; 3:e4057.
40. Chihota VN, Grant AD, Fielding K, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis 2010; 14:1024-31.
41. cuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 2008; 47:487-95.
42. Small PM. Strengthening laboratory services for today and tomorrow. Plenary Lecture given during the 38th Union World Lung Conference on Lung Health, Cape Town, South Africa, 8-12 November 2007. Int J Tuberc Lung Dis 2008; 12:1105-9.
43. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181:80-6.
44. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drugresistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14:1233-43.
45. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372:1403-9.
46. Shah NS, Richardson JR, Moodley P, et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2009; 17:510-3.
47. Buthelezi SSS. Situational analysis of TB drug resistance in KwaZulu- Natal Province: Republic of South Africa. In: Program and abstracts of the 2nd Meeting of the Global XDR TB Task Force. Geneva, Switzerland: World Health Organization, 2008.
48. Brust JCM, Moll A, Scott M, et al. Community-based treatment of multidrug-resistant tuberculosis (MDR TB) and HIV in rural South Africa. In Program and abstracts of the XVII International AIDS Conference (Mexico City,Mexico). Geneva, Switzerland: International AIDS Society, 2009.
49. IOM (Institute of Medicine). Addressing the threat of drug-resistant tuberculosis: a realistic assessment of the challenge: workshop summary. Washington, DC: National Academies Press, 2009.
50. Griffin AM, Caviedes L, Gilman R, et al. Field and laboratory preparedness: challenges to rolling out new multidrug-resistant tuberculosis diagnostics. Rev Panam Salud Publica 2009; 26:120-7.